Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-21-000580
Filing Date
2021-02-16
Accepted
2021-02-16 16:01:59
Documents
63
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT sonoma_10q-123120.htm 10-Q 602800
2 CERTIFICATION OF CHIEF EXECUTIVE OFFICER sonoma_ex3101.htm EX-31.1 8607
3 CERTIFICATION OF CHIEF FINANCIAL OFFICER sonoma_ex3102.htm EX-31.2 8428
4 CERTIFICATION sonoma_ex3201.htm EX-32.1 5269
  Complete submission text file 0001683168-21-000580.txt   3448937

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE snoa-20201231.xml EX-101.INS 624755
6 XBRL SCHEMA FILE snoa-20201231.xsd EX-101.SCH 31893
7 XBRL CALCULATION FILE snoa-20201231_cal.xml EX-101.CAL 60898
8 XBRL DEFINITION FILE snoa-20201231_def.xml EX-101.DEF 137082
9 XBRL LABEL FILE snoa-20201231_lab.xml EX-101.LAB 277431
10 XBRL PRESENTATION FILE snoa-20201231_pre.xml EX-101.PRE 230093
Mailing Address 645 MOLLY LANE, SUITE 150 WOODSTOCK GA 30189
Business Address 645 MOLLY LANE, SUITE 150 WOODSTOCK GA 30189 800-759-9305
Sonoma Pharmaceuticals, Inc. (Filer) CIK: 0001367083 (see all company filings)

EIN.: 680423298 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-33216 | Film No.: 21637833
SIC: 2834 Pharmaceutical Preparations